EP1024696A4 - Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires - Google Patents

Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires

Info

Publication number
EP1024696A4
EP1024696A4 EP98957328A EP98957328A EP1024696A4 EP 1024696 A4 EP1024696 A4 EP 1024696A4 EP 98957328 A EP98957328 A EP 98957328A EP 98957328 A EP98957328 A EP 98957328A EP 1024696 A4 EP1024696 A4 EP 1024696A4
Authority
EP
European Patent Office
Prior art keywords
cardio
reducing
combination therapy
cerebrovascular disease
risks associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98957328A
Other languages
German (de)
English (en)
Other versions
EP1024696A1 (fr
Inventor
Melvin Winokur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806688.9A external-priority patent/GB9806688D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1024696A1 publication Critical patent/EP1024696A1/fr
Publication of EP1024696A4 publication Critical patent/EP1024696A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98957328A 1997-10-22 1998-10-16 Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires Withdrawn EP1024696A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6269197P 1997-10-22 1997-10-22
US62691P 1997-10-22
GBGB9806688.9A GB9806688D0 (en) 1998-03-27 1998-03-27 Combination therapy for reducing the risks associated with cardio-and cerebrovascular diease
GB9806688 1998-03-27
PCT/US1998/021901 WO1999020110A1 (fr) 1997-10-22 1998-10-16 Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires

Publications (2)

Publication Number Publication Date
EP1024696A1 EP1024696A1 (fr) 2000-08-09
EP1024696A4 true EP1024696A4 (fr) 2004-07-14

Family

ID=26313383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98957328A Withdrawn EP1024696A4 (fr) 1997-10-22 1998-10-16 Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires

Country Status (5)

Country Link
EP (1) EP1024696A4 (fr)
JP (1) JP2001520174A (fr)
AU (1) AU753657B2 (fr)
CA (1) CA2306646A1 (fr)
WO (1) WO1999020110A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6620834B1 (en) * 1999-07-02 2003-09-16 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
JP2003523330A (ja) 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
DK1303265T3 (da) 2000-07-20 2007-11-12 Lauras As Anvendelse af COX-2-inhibitorer, som immunostimulerende midler ved behandling af HIV eller AIDS
AU2002213050A1 (en) * 2000-10-06 2002-04-15 F. Timothy Guilford A combination and method of treatment of cancer utilizing a cox-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa) reductase inhibitor
US6534540B2 (en) 2000-10-06 2003-03-18 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
WO2002094021A1 (fr) * 2000-10-06 2002-11-28 Probiochem, Llc Combinaison et methode de traitement par un inhibiteur de la cox-2, un inhibiteur de la hmg-coa et la cystine pour ameliorer la fonction du glutathion
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
WO2004006919A1 (fr) * 2002-07-11 2004-01-22 Sankyo Company, Limited Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
EP2808015A1 (fr) 2005-05-31 2014-12-03 Mylan Laboratories, Inc Compositions comportant du nebivolol
US20070037797A1 (en) * 2005-08-15 2007-02-15 Hellstrom Harold R Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
EP2770978B1 (fr) 2011-10-28 2018-01-10 Vitalis LLC Compositions anti-bouffée

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671170A1 (fr) * 1994-03-11 1995-09-13 Bristol-Myers Squibb Company Utilisation de la pravastatin pour décéler la progression de l'athéroschlérose des artères coronaires
WO1997032575A1 (fr) * 1996-03-05 1997-09-12 Children's Hospital Medical Center Derives mercapto utilises en qualite d'inhibiteurs de cyclo-oxygenases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039144A1 (fr) * 1995-06-06 1996-12-12 Procyte Corporation Complexes cuivreux stables utilises comme substances a activite therapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671170A1 (fr) * 1994-03-11 1995-09-13 Bristol-Myers Squibb Company Utilisation de la pravastatin pour décéler la progression de l'athéroschlérose des artères coronaires
WO1997032575A1 (fr) * 1996-03-05 1997-09-12 Children's Hospital Medical Center Derives mercapto utilises en qualite d'inhibiteurs de cyclo-oxygenases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9920110A1 *

Also Published As

Publication number Publication date
CA2306646A1 (fr) 1999-04-29
AU753657B2 (en) 2002-10-24
EP1024696A1 (fr) 2000-08-09
WO1999020110A1 (fr) 1999-04-29
JP2001520174A (ja) 2001-10-30
AU1361299A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
EP0904082A4 (fr) Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire
EG24678A (en) Combination therapy
ZA987844B (en) Therapeutic combinations.
AP2002002661A0 (en) Combination therapy for oesteoporosis
EP0946178A4 (fr) Traitement combine destine a reduire les risques de maladies cardio-vasculaires
ZA987843B (en) Combination therapy.
EP1024696A4 (fr) Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires
IL127306A0 (en) Combination therapy
IL131692A0 (en) Car body with body framework
GB9700939D0 (en) Therapy
GB9816556D0 (en) Therapy
GB9705200D0 (en) Well treatment with particles
GB9704112D0 (en) The Sandelver
GB9703633D0 (en) Cancer therapy
EP0676185A3 (fr) Cabine individuelle de sauna.
GB9806688D0 (en) Combination therapy for reducing the risks associated with cardio-and cerebrovascular diease
GB9621970D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9612082D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9616804D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9806039D0 (en) Therapy
TW331146U (en) Far infrared healthy cabin
TW352126U (en) Structure improvement for door inside the door
TW352786U (en) Structure for door inside the door
GB9704885D0 (en) Therapy
GB9727507D0 (en) The door mate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000522;LT PAYMENT 20000522;LV PAYMENT 20000522;MK PAYMENT 20000522;RO PAYMENT 20000522;SI PAYMENT 20000522

A4 Supplementary search report drawn up and despatched

Effective date: 20040601

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 01N 43/16 A

17Q First examination report despatched

Effective date: 20041110

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060210